Anticardiolipin antibodies in various diseases in Taiwan: a retrospective analysis

Abstract

The goals of this study are to determine the frequency of anticardiolipinantibodies (ACA) in patients with various diseases and to evaluate the clinical significance of ACA in Taiwan. We collected 690 patients from ACA laboratory records. They were divided into eight groups in order to compare ACA percentages. Positive rates of ACA in different disease groups were below 20%, except for 38.2% in autoimmune diseases with vascular thrombosis. Compared with old stroke, the ACA positivity in young stroke was not significantly different (P 0.482). The positive percentage of lupus anticoagulant (LA) (2.86%) was lower than that of ACA (15.66%) in young stroke (P 0.015). Among patients with pregnancy loss or prematurity, the ACA positivity in lupus patients (44.44%) was higher than without lupus (9.76%; P 0.01). The prevalence of ACA is higher in patients with vascular thrombosis complicated by autoimmune diseases than with thrombosis alone in Taiwan. Young and old stroke do not differ in ACA positivity. Moreover, ACA is more prevalent than LA for young stroke related coagulation.The ACA positivity for pregnancy loss or prematurity is very low in Taiwan. In summary, this is the first report on the frequency of ACA and other coagulation factors in various diseases in Taiwan.

Keywords

anticardiolipin antibodies autoimmune diseases pregnancy loss stroke vascular thrombosis

Get full access to this article

View all access options for this article.

References

Asherson RA , Harris EN. Anticardiolipin antibodies—clinical associations . Postgrad Med J 1986; 62: 1081-1087 .

Hughes GRV. The antiphospholipid syndrome: Ten years on . Lancet 1993; 342: 341-344 .

Briley DP , Coull BM , Goodnight SH Jr. Neurological disease associated with antiphospholipid antibodies . Ann Neurol 1989; 25: 221-227 .

Fields RA , Toubbeh H , Searles RP , Bankhurst AD. The prevalence of anticardiolipin antibodies in a healthy elderly population and its association with antinuclear antibodies . J Rheumatol 1989; 16: 623-625 .

Shi W , Krilis SA , Chong BH , Gordon S , Chesterman CN. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population . Aust NZ J Med 1990; 20: 231-236 .

Jones HW , Ireland R , Sennldi G et al. Antiphospholipid antibodies in patients with Malaysia with systemic lupus erythematosus . Ann Rheum Dis 1991; 50: 173-175 .

Picillo U , Migliaresi S , Marcialis MR , Longobardo A , La Palombara F , Tirri G. Longitudinal survey of anticardiolipin antibodies in systemic lupus erythematosus . Scand J Rheumatol 1992; 21: 271-276 .

Comp PC. Congenital and acquired hypercoagulable states. In: Hull R , Pineo GF (eds) Disorders of Thrombosis. WB Saunders: Philadelphia , 1996, p 339-339.

Harris EN , Asherson RA , Hughes GRV. Antiphospholipid antibodies—autoantibodies with a difference . Annu Rev Med 1988; 39: 261-261 .

10.

Counts RB. A solid-phase immunoradiometric assay of factor VIII protein . Br J Haematol 1975; 31: 429-429 .

11.

Oosting JD , Derksen RHWM , Bobbink IWG et al. Anticardiolipin antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S—an explanation for their pathogenic mechanism ? Blood 1993; 81: 2618-2625 .

12.

Yin ET , Wessler S , Stoll PJ. Biological properties of the naturally occurring plasma inhibitor to activated factor X . J Biol Chem 1971; 246: 3703-3703 .

13.

Blomback B , Hogg DH , Gardlund B et al. Fibrinogen and fibrin formation . Thromb Res 1976; 8: 329-329 .

14.

Ames PR , Alves J , Pap AF , Ramos P , Khamashta MA , Hughes GRV. Fibrinogen in systemic lupus erythematosus: more than an acute phase reactant ? J Rheumatol 2000; 27: 1190-1195 .

15.

Asherson RA , Khamashta MA , Gil A et al. Cerebrovascular disease and antiphospholipidantibodies in systemic lupus erythematosus, lupus-like disease, and the primary antiphospholipid syndrome . Am J Med 1989; 86: 391-399 .

16.

Hess DC , Krauss J , Adams RJ , Nichols FT , Zhang D-I , Rountree HA. Anticardiolipin antibodies: A study of frequency in TIA and stroke . Neurology 1991; 41: 525-528 .

17.

Levine SR , Deegan MJ , Futrell N , Welch KMA. Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases . Neurology 1990; 40: 1181-1189 .

18.

The Antiphospholipid Antibodies in Stroke Study Group . Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia . Stroke 1990; 21: 1268-1273 .

19.

Yatsu FM. Other cerebrovascular syndrome. In: Rowland LP (ed) Merritt’s Textbook of Neurology, 9th ed. Williams and Wilkins: New York , 1995, 257-262.

20.

Petri M. Pathogenesis and treatment of the antiphospholipid antibody syndrome . Med Clin N Am 1997; 81: 151-177 .

21.

Wilson WA , Gharavi AE , Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report on an international workshop . Arthritis Rheum 1999; 42: 1309-1311 .

22.

Gharavi AE , Harris EN , Asherson RA , Hughes GRV. Anticardiolipin antibodies: isotype distribution and phospholipidspecificity . Ann Rheum Dis 1987; 46: 1-6 .

23.

Harris EN , Gharavi AE , Patel SP , Hughes GRV. Evaluation of the anticardiolipin antibody test: report of an international workshop held 4th April 1986 . Clin Exp Immunol 1987; 68: 215-222 .

24.

Exner T , Papadopoulos G , Koutts J. Use of a simplified dilute Russell’s viper venom time (DRVVT) confirms heterogeneity among “lupus anticoagulants” . Blood Coag Fibrinol 1990; 1: 259-266 .

25.

Zivelin A , Gitel S , Griffin JH et al. Extensive venous and arterial thrombosis associated with an inhibitor to activated protein C . Blood 1999; 94: 895-901 .

26.

Dykes AC , Walker ID , McMahon AD , Islam SI , Tait RC. A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state . Br J Haematol 2001; 113: 636-641 .

27.

Dunzendorfer S , Kaneider N , Rabensteiner A et al. Cell-surface heparan sulfate proteoglycan-mediated regulation of human neutrophil migration by the serpin antithrombin III . Blood 2001; 97: 1079-1085 .

28.

Balasubramanian V , Grusin NK , Bucher RW , Turitto VT , Slack SM. Residence-time dependent changes in fibrinogen adsorbed to polymeric biomaterials . J Biomed Mater Res 1999; 44: 253-260 .

29.

Hirsh J , Piovella F , Pini M. Congenital antithrombin III deficiency . Am J Med 1989; 87(S): 34S-38S .

30.

Harris EN , Gharavi AE , Asherson RA , Boey ML , Hughes GRV. Cerebral infarction in systemic lupus erythematosus: association with antic-ardiolipin antibodies . Clin Exp Rheumatol 1984; 2: 47-51 .

31.

Montalban J , Rio J , Khamastha M et al. Value of immunologic testing in stroke patients. A prospective multicenter study . Stroke 1994; 25: 2412-2415 .

32.

Brey RL , Hart RG , Sherman DG , Tegeler CH. Antiphospholipid antibodies and cerebral ischemia in young people . Neurology 1990; 40: 1190-1196 .

33.

Chancellor AM , Glasgow GL , Ockelford PA , Johns A , Smith J. Etiology, prognosis, and hemostatic function after cerebral infarction in young adults . Stroke 1989; 20: 477-482 .

34.

Vaarala O , Alfthan G , Jauhiainen M et al. Cross reaction between antibodies to oxidized low-density lipoprotein and to cardiolipin in systemic lupus erythematosus . Lancet 1993; 341: 923-925 .

35.

Kattwinkel N , Billanueva AG , Labib SB et al. Myocardial infarction caused by cardiac microvasculopathy in a patient with the primary antiphospholipid syndrome . Ann Intern Med 1992; 116: 974-976 .

36.

Hamsten A , Norberg R , Bjorkholm M , De Faire U , Holm G. Antibodies to cardiolipin in young survivors of myocardial infarction: an association with recurrent cardiovascular events . Lancet 1986; 1: 113-115 .

37.

Phadke KV , Phillips RA , Clarke DT , Jones M , Naish P , Carson P. Anticardiolipin antibodies in ischemic heart disease: marker or myth ? Br Heart J 1993; 69: 391-394 .

38.

Ginsburg KS , Liang MH , Newcomer L et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis . Ann Intern Med 1992; 117: 997-1002 .

39.

Mateo J , Oliver A , Borrell M , Sala N , Fontcubetra J. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism—results of the Spanish Multicentric Study on Thrombophilia (EMET-Study) . Thromb Hae-most 1997; 77: 444-451 .

40.

Zanon E , Prandoni P , Vianello F et al. Anti-beta2-glycoprotein I antibodies in patients with acute venous thromboembolism: prevalence and association with recurrent thromboembolism . Thromb Res 1999; 96: 269-274 .

41.

Love PE , Santoro SA. Antiphospholipid antibodies, anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders . Ann Intern Med 1990; 112: 682-689 .

42.

Ginsberg JS , Wells PS , Brill-Edwards P et al. Antiphospholipid antibodies and venous thromboembolism . Blood 1995; 86: 3685-3691 .

43.

Nencini P , Baruffi C , Abbate R , Massai G , Amaducci L , Inzitari D. Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia . Stroke 1992; 23: 189-193 .

44.

Hart RG , Miller VT , Coull BM , Bril V. Cerebral infarction associated with lupus anticoagulants: Preliminary report . Stroke 1984: 15: 114-118 .

45.

Hankey GJ , Eikelboom JW , van Bockxmeer FM et al. Inherited thrombophilia in ischemic stroke and its pathogenic subtypes . Stroke 2001; 32: 1793-1799 .

46.

Nojima J , Kuratsune H , Suehisa E et al. Association between the prevalence of antibodies to beta 2-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications . Clin Chem 2001; 47: 1008-1015 .

47.

Ko GTC , Yeung VTF , Chan JCN et al. Plasma fibrinogen concentration in a Chinese population . Atherosclerosis 1997; 131: 211-217 .

48.

Asherson RA , Liote F , Page B et al. Avascular necrosis of bone and antiphospholipid antibodies in systemic lupus erythematosus . J Rheumatol 1993; 20: 284-287 .

49.

Seleznick MJ , Silveira LH , Espinoza LR. Avascular necrosis associated with anticardiolipin antibodies . J Rheumatol 1991; 18: 1416-1417 .

50.

Branch DW. Thoughts on the mechanism of pregnancy loss associated with the antiphospholipid syndrome . Lupus 1994; 3: 275-280 .

51.

Lynch A , Byers T , Emlen W , Rynes D , Shetterly SM , Hamman RF. Association of antibodies to beta2-glycoprotein 1 with pregnancy loss and pregnancy-induced hypertension: a prospective study in low-risk pregnancy . Obstet Gynecol 1999; 93: 193-198 .

52.

Simpson JL , Carson SA , Chesney C et al. Lack of association between antiphospholipid antibodies and first-trimester spontaneous abortion: prospective study of pregnancies detected within 21 days of conception . Fertil Steril 1998; 69: 814-820 .

53.

Teixido M , Font J , Reverter JC et al. Anti-beta 2-glycoprotein I antibodies: a useful marker for the antiphospholipid syndrome . Br J Rheumatol 1997; 36: 113-116 .

54.

Out HJ , Bruinse HW , Christiaens GCML et al. Prevalence of antiphospholipid antibodies in patients with fetal loss . Ann Rheum Dis 1991; 50: 553-557 .

55.

Asherson RA , Cervera R. The antiphospholipid syndrome. In: Lahita RG , Chiorazzi N , Reeves WH (eds) Textbook of the Autoimmune Diseases, 5th edition. Lippincott William & Wilkins: New York , 2000, 641-668.

56.

Petri M. Clinical and management aspects of the antiphospholipid syndrome. In: Wallace DF , Hahn BH (eds). Dubois’ Lupus Erythematosus, 5th edition. Williams & Wilkins: Baltimore , 1997, p 57-57.